title: Multifocal electrophysiologic findings after intravitreal bevacizumab (avastin) treatment.
abstract: OBJECTIVE
  To determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography testing.
  
  
  METHODS
  Thirty-one eyes with choroidal neovascularization, proliferative diabetic retinopathy, and retinal vein occlusion received intravitreal bevacizumab (2.5 mg/0.1 mL). All patients underwent best-corrected visual acuity measurement, retinal fluorescein angiography, optical coherence tomography, and multifocal electroretinography at baseline and 1 month after the treatment.
  
  
  RESULTS
  Subjects undergoing multifocal electroretinography testing had no statistically significant changes in electrophysiologic responses 1 month after the intravitreal injection of bevacizumab.
  
  
  CONCLUSIONS
  Multifocal electrophysiologic testing did not demonstrate any short-term cone photoreceptor toxicity after intravitreal bevacizumab.
authors: Retina Service, Asociación Para Evitar la Ceguera en México, Hospital Dr. Luis Sánchez Bulnes, Mexico City, México. mitzytorres@yahoo.com
authors: Mitzy E
authors: ME
authors: Torres-Soriano
authors: Victoria
authors: V
authors: Cubas-Lorenzo
authors: Gerardo
authors: G
authors: García-Aguirre
authors: Myrian
authors: M
authors: Hernández-Rojas
authors: Verónica
authors: V
authors: Kon-Jara
authors: Joséluis
authors: J
authors: Díaz-Rubio
authors: Jans
authors: J
authors: Fromow-Guerra
authors: Hugo
authors: H
authors: Quiroz-Mercado
authors: Juan M
authors: JM
authors: Jiménez-Sierra
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D004596:Electroretinography / Q000187:drug effects; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D011446:Prospective Studies; D012160:Retina / Q000502:physiology*; D012170:Retinal Vein Occlusion / Q000188:drug therapy* / Q000503:physiopathology; D019233:Retreatment; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab